Privately held Bellicum Pharmaceuticals Inc. added another $14.7 million from existing investors, including AVG Ventures and Remeditex Ventures, to its fully subscribed Series B, ratcheting the total raise from the round to $34.4 million and extending the company’s runway into 2015.